Copyright
©The Author(s) 2024.
World J Gastroenterol. Jan 14, 2024; 30(2): 146-157
Published online Jan 14, 2024. doi: 10.3748/wjg.v30.i2.146
Published online Jan 14, 2024. doi: 10.3748/wjg.v30.i2.146
Table 1 Clinical characteristics of eosinophilic gastroenteritis patients in this cohort, n (%)
| All patients (N = 55) | |||||
| Demographic characteristics | Complications | ESR (mm/h)2 | 4.00 [2.00, 8.00] | ||
| Sex, female | 31 (56.4) | Ascite | 17 (30.9) | Elevated ESR (> 15) | 7 (7/49, 14.3) |
| Age (yr)2 | 38.00 [25.50, 50.00] | Intestinal obstruction | 8 (14.5) | CRP (mg/L)2 | 1.62 [0.84, 4.38] |
| BMI (kg/m2)1 | 23.28 ± 3.96 | Comorbidities | Elevated hsCRP (> 3) | 11 (11/53, 20.8) | |
| BMI > 24 | 21 (38.9) | Hp infection | 16 (16/50, 32.0) | ANA (+) | 8 (8/47, 17.0) |
| Clinical manifestations | HTN | 8 (14.5) | ANCA (+) | 4 (4/46, 8.7) | |
| Disease duration (mo)2 | 5.00 [1.00, 30.00] | DM | 3 (5.5) | Allergen test (+) | 14 (14/28, 50.0) |
| Allergic history | 18 (32.7) | HBV infection | 4 (7.3) | Inhalant allergen | 8 (8/25, 32.0) |
| Allergic rhinitis | 10 (18.2) | Klein classification | Food allergen | 8 (8/27, 29.6) | |
| Asthma | 11 (20.0) | Mucosal type | 28 (50.9) | Endoscopy findings | |
| Urticaria | 2 (3.6) | Muscular type | 9 (16.4) | Duodenum involvement | 40 (40/54, 74.1) |
| Symptoms, n (%) | Serosal type | 18 (32.7) | Bulb | 27 (27/54, 50.0) | |
| Abdominal pain | 49 (89.1) | Laboratory tests | Post-bulb | 16 (16/54, 29.6) | |
| Diarrhea | 34 (61.8) | EOS (× 109/L)2 | 1.16 [0.67, 3.91] | Descending part | 29 (29/54, 55.6) |
| Nausea | 29 (52.7) | Hb (g/L)1 | 138.36 ± 14.81 | Hyperaemia | 31 (31/54, 57.4) |
| Vomiting | 26 (47.3) | PLT (× 109/L)1 | 279.29 ± 81.84 | Erosion | 13 (13/54, 24.1) |
| Distension | 27 (49.1) | Alb (g/L)2 | 40.00 [37.00, 42.00] | Ulcer | 5 (5/54, 9.3) |
| GI bleeding | 3 (5.5) | IgE (KU/L)2 | 152.00 [66.55, 335.50] | Therapy | |
| Weight loss | 36 (65.5) | > 60 | 38 (79.2) | Diet therapy | 7 (12.7) |
| Fever | 4 (7.3) | > 300 | 13 (27.1) | Anti-allergic agents | 7 (12.7) |
| Rash | 6 (10.9) | Immunosuppressors | 3 (5.5) | ||
Table 2 Clinical characteristics and intergroup comparisons
| Non glucocorticoid treatment (n = 12) | Glucocorticoid treatment (n = 43) | P value | Non-glucocorticoid dependent (n = 22) | Glucocorticoid dependent (n = 21) | P value | |
| Sex (female) | 8 (66.7) | 23 (53.5) | 0.519 | 10 (45.5) | 13 (61.9) | 0.364 |
| Age (yr)2 | 44.00 [27.75, 48.75] | 36.00 [25.00, 50.00] | 0.838 | 36.00 [26.00, 53.25] | 36.00 [25.00, 48.00] | 0.780 |
| BMI (kg/m2)1 | 23.43 ± 2.84 | 23.24 (4.25) | 0.888 | 24.51 (4.55) | 21.85 (3.50) | 0.041a |
| Disease duration (mo) | 2.00 [1.00, 10.00] | 7.00 [1.00, 41.00] | 0.223 | 3.00 [1.00, 15.75] | 11.00 [4.00, 60.00] | 0.056b |
| Allergic history | 2 (16.7) | 16 (37.2) | 0.298 | 8 (36.4) | 8 (38.1) | 1.000 |
| Symptoms | ||||||
| Abdominal pain | 11 (91.7) | 38 (88.4) | 1.000 | 19 (86.4) | 19 (90.5) | 1.000 |
| Diarrhea | 8 (66.7) | 26 (60.5) | 0.750 | 12 (54.5) | 14 (66.7) | 0.537 |
| Vomiting | 3 (25.0) | 23 (53.5) | 0.108 | 12 (54.5) | 11 (52.4) | 1.000 |
| Weight loss | 10 (83.3) | 26 (60.5) | 0.183 | 14 (63.6) | 12 (57.1) | 0.760 |
| Hp infection | 5 (5/11, 45.5) | 11 (11/39, 28.2) | 0.297 | 6 (6/20, 30.0) | 5 (5/19, 26.3) | 1.000 |
| Klein classification | ||||||
| Mucosal type | 6 (50.0) | 22 (51.2) | 1.000 | 11 (50.0) | 11 (52.4) | 0.298 |
| Muscular type | 2 (16.7) | 7 (16.3) | 2 (9.1) | 5 (23.8) | ||
| Serosal type | 4 (33.3) | 14 (32.6) | 9 (40.9) | 5 (23.8) | ||
| EOS (× 109/L)2 | 0.76 [0.51, 2.32] | 1.48 [0.95, 4.00] | 0.124 | 2.46 [1.13, 3.96] | 1.01 [0.48, 3.99] | 0.065b |
| IgE (KU/L)2 | 54.50 [23.77, 629.75] | 166.00 [72.90, 298.00] | 0.406 | 234.00 [118.00, 343.25] | 118.00 [67.10,191.00] | 0.082b |
| Elevated IgE (> 60) | 5 (5/10, 50.0) | 33 (33/36, 86.8) | 0.022a | 17 (17/20, 85.0) | 16 (16/18, 88.9) | 1.000 |
| Duodenum involvement | 7 (7/11, 63.6) | 33 (33/43, 76.7) | 0.448 | 15 (68.2) | 18 (85.7) | 0.281 |
| Bulb | 5 (5/11, 45.5) | 21 (21/43, 48.8) | 1.000 | 9 (40.9) | 13 (61.9) | 0.227 |
| Post-bulb | 1 (1/11, 9.1) | 15 (15/43, 34.9) | 0.144 | 11 (50.0) | 4 (19.0) | 0.055b |
| Descending part | 3 (3/11, 27.3) | 27 (27/43, 62.8) | 0.046a | 12 (54.5) | 15 (71.4) | 0.347 |
| Duodenum endoscopic features | ||||||
| Hyperaemia | 6 (6/11, 54.5) | 25 (25/43, 58.1) | 1.000 | 14 (63.6) | 11 (52.4) | 0.543 |
| Erosion | 3 (3/11, 27.3) | 10 (10/43, 23.3) | 1.000 | 4 (18.2) | 6 (28.6) | 0.488 |
| Ulcer | 1 (1/11, 9.1) | 4 (4/43, 9.3) | 1.000 | 0 (0.0) | 4 (19.0) | 0.048a |
Table 3 Univariate and multivariate Cox analysis for disease relapse
| Univariate analysis | Multivariate analysis | ||||
| HR (95%CI) | P value | Coef | HR (95%CI) | P value | |
| Age (yr) | |||||
| > 40 | 1 | 0.044a | 1 | 0.330 | |
| ≤ 40 | 2.0408 (1.0082-4.1312) | 0.6827 | 1.9791 (0.5013-7.8140) | ||
| BMI (kg/m2) | |||||
| ≤ 24 | 1 | 0.014a | 1 | 0.037a | |
| > 24 | 0.3922 (0.1916-0.8027) | -1.1375 | 0.3206 (0.11-0.9347) | ||
| Disease duration (mo) | |||||
| ≤ 3.5 | 1 | 0.011a | 1 | 0.106 | |
| > 3.5 | 2.4725 (1.2200-5.0110) | 0.7447 | 2.1058 (0.8533-5.1968) | ||
| Vomiting | |||||
| No | 1 | 0.001a | 1 | 0.695 | |
| Yes | 3.1259 (1.5246-6.4093) | 0.2677 | 1.3069 (0.3423-4.9904) | ||
| T-IgE (KU/L) | |||||
| ≤ 300 | 1 | 0.022a | 1 | 0.233 | |
| > 300 | 0.2773 (0.1204-0.6384) | -0.7995 | 0.4496 (0.121-1.6699) | ||
| Glucocorticoid treatment | |||||
| No | 1 | 0.003a | 1 | 0.065b | |
| Yes | 6.1434 (2.8446-13.2676) | 1.4038 | 4.0705 (0.917-18.0689) | ||
- Citation: Li KW, Ruan GC, Liu S, Xu TM, Ma Y, Zhou WX, Liu W, Zhao PY, Du ZR, Li J, Li JN. Long-term prognosis and its associated predictive factors in patients with eosinophilic gastroenteritis. World J Gastroenterol 2024; 30(2): 146-157
- URL: https://www.wjgnet.com/1007-9327/full/v30/i2/146.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i2.146